Indoco Remedies shares jumped 3% after the company received final approval from the USFDA for its generic version of Cetirizine Hydrochloride Tablets USP, 10 mg.
This over-the-counter medication is a generic equivalent of Johnson & Johnson Consumer Inc.’s Zyrtec Allergy Tablets, 10 mg. The tablets, which are used to treat hay fever and other allergy conditions, will be manufactured at Indoco’s Goa facility in India.
As of 12:08 pm, Indoco Remedies shares were trading 2.64% higher at Rs 348.50 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
